• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Supported By

IP-Watch offers the opportunity for third parties to provide financial support for our work without influencing the editorial independence of our content. Funding proposals to sponsor new or existing projects and reporting must be approved by the editor-in-chief in consultation with appropriate members of our team. A funder whose branding appears on editorial content may have a role in suggesting topics for consideration, but the IP-Watch editor is not obliged to accept ideas from the funder. The content is written and edited by IP-Watch journalists to our normal standards. We do not show draft articles to funders for approval.

Civil Society And TRIPS Flexibilities Series – Translations Now Available

20/08/2018 by Intellectual Property Watch, Intellectual Property Watch Leave a Comment

Patients around the world, in developing and developed countries, are encountering barriers to access to affordable medical products, in part due to patents and resulting high prices. This is occurring despite longstanding protections built into international trade rules to allow smaller economies to act on behalf of their people and make such medical products available regardless of patents. These protections are often referred to as flexibilities in the 1994 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The prevailing view is that knowledge, understanding and use of them remains limited among policymakers and many potential beneficiaries, even as patent-strong nations and their industries work to narrow the reach and ability to use these flexibilities. In the face of this, global civil society in recent years have increasingly begun work to change the direction of this trend, with the ultimate goal of helping people everywhere – but particularly poor populations – obtain drugs they need that exist but are out of their reach. Now, the series of Intellectual Property Watch stories on this subject sponsored by Make Medicines Affordable have been translated into five languages.

Filed Under: IP Policies, Language, Themes, Venues, English, Health & IP, Lobbying, Patents/Designs/Trade Secrets, Supported By, TRIPS Flexibilities, Technical Cooperation/ Technology Transfer, WTO/TRIPS

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

20/06/2018 by Intellectual Property Watch 15 Comments

Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property, health, technology transfer, investment policy and especially their impact on developing countries. He has authored several books and academic articles and been a visiting professor at several universities. Additionally, he has consulted with many United Nations agencies, the World Bank, and other regional and international organisations and has advised several governments on intellectual property, innovation policy and public health. Correa was a member of the UK Commission on Intellectual Property, of the Commission on Intellectual Property, Innovation and Public Health established by the World Health Assembly and of the FAO Panel of Eminent Experts on Ethics in Food and Agriculture.

Currently, he is the Director of the Centre for Interdisciplinary Studies on Industrial Property and Economics Law, at the University of Buenos Aires. He takes over as the Executive Director of the Secretariat of the Geneva-based South Centre from 1 July 2018. Correa recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is number two of two. The first was with Dr Othoman Mellouk.]

Filed Under: Features, Inside Views, IP Policies, Themes, Venues, Development, English, Health & IP, Human Rights, Innovation/ R&D, Patents/Designs/Trade Secrets, Supported By, TRIPS Flexibilities, Technical Cooperation/ Technology Transfer, United Nations - other, WTO/TRIPS

The Myth Behind Health And Trade Agreements – Q&A With Othoman Mellouk

18/06/2018 by Intellectual Property Watch 12 Comments

Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade. He is the Intellectual Property and Access to Medicines Lead at the international treatment preparedness coalition (ITPC), a global network of people living with HIV and their advocates working together to achieve access to HIV and Viral Hepatitis and a member of the WHO Strategic and Technical Advisory Committee on HIV and Hepatitis. Dr Mellouk started off in the Association for the Fight against AIDS which has been at the forefront of the response to HIV in Morocco and the introduction of the first anti-HIV generic medicines in the country. In a series supported by the Make Medicines Affordable organisation, Mellouk recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is one of two. An interview with Carlos Correa will follow.]

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, Bilateral/Regional Negotiations, Development, English, Finance, Health & IP, Human Rights, Patents/Designs/Trade Secrets, TRIPS Flexibilities, Technical Cooperation/ Technology Transfer, WTO/TRIPS

Five Years After The Indian Supreme Court’s Novartis Verdict

20/05/2018 by Patralekha Chatterjee for Intellectual Property Watch 13 Comments

On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about patents and patients. India’s apex court delivered a 112-page landmark judgement which dismissed Swiss pharma giant Novartis AG’s appeal for a patent for its life-saving cancer drug marketed under brand name Glivec in most parts of the world. The Novartis case triggered a hugely polarising discourse around the world about a key feature of India’s patent regime.

Filed Under: IP Policies, Language, Themes, Venues, Asia/Pacific, English, Europe, Health & IP, Health Policy Watch, IP Law, Innovation/ R&D, Lobbying, Patents/Designs/Trade Secrets, Regional Policy, Supported By, TRIPS Flexibilities

Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say

18/05/2018 by Dugie Standeford for Intellectual Property Watch 17 Comments

For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say.

Filed Under: IP Policies, Language, Themes, Venues, Asia/Pacific, Development, English, Finance, Health & IP, Health Policy Watch, Human Rights, Innovation/ R&D, Latin America/Caribbean, Lobbying, Patents/Designs/Trade Secrets, Regional Policy, Supported By, TRIPS Flexibilities, Technical Cooperation/ Technology Transfer, WTO/TRIPS

Groups Target EU-Mercosur FTA To Advance Access To Health In Trade Deals

16/05/2018 by Monika Ermert for Intellectual Property Watch 12 Comments

AIDS activists, health activists and civil society organizations in Brazil and Argentina are pushing back against the negative effects of the planned free trade agreement between the Mercosur countries and the European Union. The EU-Mercosur negotiations might be the best chance as of now to advance an intellectual property agenda that is more favourable to access to health, says Pedro Villardi, coordinator on IP policy issues at the Associação Brasiliera Interdisciplinar de Aids Observatorio National de Politicas de Aids (ABIA).

Filed Under: Language, Themes, Venues, English, Europe, Finance, Health & IP, Health Policy Watch, Latin America/Caribbean, Regional Policy, Supported By, TRIPS Flexibilities, WTO/TRIPS

Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents

10/05/2018 by Catherine Saez, Intellectual Property Watch 14 Comments

Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries, civil society organised itself to increase access to sofosbuvir for millions in need.

Filed Under: Features, IP Policies, Language, Themes, Venues, Africa, Asia/Pacific, Development, English, Health & IP, Health Policy Watch, Innovation/ R&D, Lobbying, North America, Patents/Designs/Trade Secrets, Regional Policy, Supported By, TRIPS Flexibilities, Technical Cooperation/ Technology Transfer

Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition

08/05/2018 by Catherine Saez, Intellectual Property Watch 15 Comments

The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled.

Filed Under: Features, IP Policies, Language, Themes, Venues, English, Health & IP, Health Policy Watch, Human Rights, Innovation/ R&D, Latin America/Caribbean, Lobbying, Patents/Designs/Trade Secrets, Regional Policy, Supported By, TRIPS Flexibilities, WTO/TRIPS

Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim

07/05/2018 by Sinfah Tunsarawuth for Intellectual Property Watch 17 Comments

BANGKOK – Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said.

Filed Under: Features, IP Policies, Language, Themes, Venues, Asia/Pacific, English, Health & IP, Health Policy Watch, Innovation/ R&D, Lobbying, Patents/Designs/Trade Secrets, Regional Policy, Supported By, TRIPS Flexibilities, WHO, WTO/TRIPS

Civil Society Key In TRIPS Flexibility Implementation

04/05/2018 by Catherine Saez, Intellectual Property Watch 22 Comments

When the agreement on intellectual property was adopted by the World Trade Organization, a number of flexibilities were included in the text, mainly to give developing countries policy space to implement the agreement with development considerations. However, some countries through lack of awareness or economic pressure have not used those flexibilities fully, and found themselves facing difficulties addressing their public health needs, which some associate with this failure to use the flexibilities. Civil society has engaged in notable efforts to counter pressure and raise policymakers’ awareness for a wider access to medicines.

Filed Under: Features, IP Policies, Language, Themes, Venues, Bilateral/Regional Negotiations, Development, English, Health & IP, Health Policy Watch, Human Rights, Lobbying, Patents/Designs/Trade Secrets, Supported By, TRIPS Flexibilities, United Nations - other, WHO, WTO/TRIPS

  • 1
  • 2
  • Next Page »
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting